28 November 2022

---

BIOLASE to participate in Benchmark Discovery One-on-One Investor Conference in NYC

---

BIOLASE will participate in the 11th Annual Benchmark Discovery One-on-One Investor Conference in New York City on Dec. 1, 2022.

President and CEO John Beaver and CFO Jennifer Bright will host one-on-one meetings with investors and analysts during the event, according to a news release.

To schedule a one-on-one investor meeting with the company’s management, please contact BIOLASE’s investor relations firm, EVC Group, LLC, at tkehrli@evcgroup.com.

About BIOLASE

BIOLASE is a medical device business that develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. 

The company has sold over 43,300 laser systems from 1998 to 2021 in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.